Fibroid management in premenopausal women

References

• Donnez J, Dolmans M-M. Uterine fibroid management: from the present to the future. Hum Reprod Update 2016;22:665–86
   PubMed Web of Science ®Google Scholar
• Kim JJ, Sefton EC. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Mol Cell Endocrinol 2012;358:223–31
   PubMed Web of Science ®Google Scholar
• Bulun SE. Uterine fibroids. N Engl J Med 2013;369:1344–55
   PubMed Web of Science ®Google Scholar
• Islam MS, Protic O, Giannubilo SR, et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J Clin Endocrinol Metab 2013;98:921–34
   PubMed Web of Science ®Google Scholar
• Lumsden MA, Hamoodi I, Gupta J, Hickey M. Fibroids: diagnosis and management. BMJ 2015;351:h4887
   PubMedGoogle Scholar
• Stewart EA. Clinical practice. Uterine fibroids. N Engl J Med 2015;372:1646–55
   PubMed Web of Science ®Google Scholar
• Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003;188:100–7
   PubMed Web of Science ®Google Scholar
• Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG 2017;124:1501–12
   PubMed Web of Science ®Google Scholar
• Peddada SD, Laughlin SK, Miner K, et al. Growth of uterine leiomyomata among premenopausal black and white women. Proc Natl Acad Sci U S A2008;105:19887–92
   PubMed Web of Science ®Google Scholar
• Khan AT, Shehmar M, Gupta JK. Uterine fibroids: current perspectives. Int J Womens Health 2014;6:95–114
   PubMedGoogle Scholar
• Baird DD, Dunson DB. Why is parity protective for uterine fibroids? Epidemiology 2003;14:247–50
   PubMed Web of Science ®Google Scholar
• Laughlin SK, Schroeder JC, Baird DD. New directions in the epidemiology of uterine fibroids. Semin Reprod Med 2010;28:204–17
   PubMed Web of Science ®Google Scholar
• Makinen N, Mehine M, Tolvanen J, et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 2011;334:252–5
   PubMed Web of Science ®Google Scholar
• Islam MS, Protic O, Stortoni P, et al. Complex networks of multiple factors in the pathogenesis of uterine leiomyoma. Fertil Steril 2013;100:178–93
   PubMed Web of Science ®Google Scholar
• Styer AK, Rueda BR. The epidemiology and genetics of uterine leiomyoma. Best Pract Res Clin Obstet Gynaecol 2016;34:3–12
   PubMed Web of Science ®Google Scholar
• Mehine M, Kaasinen E, Makinen N, et al. Characterization of uterine leiomyomas by whole-genome sequencing. N Engl J Med 2013;369:43–53
   PubMed Web of Science ®Google Scholar
• Donnez J, Jadoul P. What are the implications of myomas on fertility? A need for a debate? Hum Reprod 2002;17:1424–30
   PubMed Web of Science ®Google Scholar
• Practice Committee of the American Society for Reproductive Medicine. Myomas and reproductive function. Fertil Steril 2008;90:S125–S30
   PubMed Web of Science ®Google Scholar
• Zupi E, Centini G, Sabbioni L, et al. Nonsurgical alternatives for uterine fibroids. Best Pract Res Clin Obstet Gynaecol 2016;34:122–31
   PubMed Web of Science ®Google Scholar
• Dubuisson JB, Fauconnier A, Babaki FK, Chapron C. Laparoscopic myomectomy: a current view. Hum Reprod Update 2000;6:588–94
   PubMed Web of Science ®Google Scholar
• Donnez J, Donnez O, Dolmans MM. With the advent of selective progesterone receptor modulators, what is the place of myoma surgery in current practice? Fertil Steril 2014;102:640–8
   PubMed Web of Science ®Google Scholar
• Donnez J, Vazquez F, Tomaszewski J, et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril 2014;101:1565–73 e1561-1518
   PubMed Web of Science ®Google Scholar
• Flynn M, Jamison M, Datta S, Myers E. Health care resource use for uterine fibroid tumors in the United States. Am J Obstet Gynecol 2006;195:955–64
   PubMed Web of Science ®Google Scholar
• Donnez J, Squifflet J, Donnez O. Have the safety concerns about laparoscopic hysterectomy been fully addressed? Br J Obstet Gynecol 2009;116:1272–3
   Google Scholar
• Donnez O, Jadoul P, Squifflet J, Donnez J. A series of 3190 laparoscopic hysterectomies for benign disease from 1990 to 2006: evaluation of complications compared with vaginal and abdominal procedures. Br J Obstet Gynecol 2009;116:492–500
   Google Scholar
• Donnez O, Donnez J. A series of 400 laparoscopic hysterectomies for benign disease: a single centre, single surgeon prospective study of complications confirming previous retrospective study. Br J Obstet Gynecol 2010;117:752–5
   Google Scholar
• Wise LA, Laughlin-Tommaso SK. Epidemiology of uterine fibroids: from menarche to menopause. Clin Obstet Gynecol 2016;59:2–24
   PubMed Web of Science ®Google Scholar
• Donnez J, Courtoy GE, Donnez O, Dolmans MM. Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review. Reprod Biomed Online 2018;37:216–23
   PubMed Web of Science ®Google Scholar
• Donnez J, Tomaszewski J, Vazquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012;366:421–32
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update 2005;11:293–307
   PubMed Web of Science ®Google Scholar
• Bestel E, Donnez J. The potential of selective progesterone receptor modulators for the treatment of uterine fibroids. Expert Rev Endocrinol Metab 2014;9:79–92
   PubMedGoogle Scholar
• Chabbert-Buffet N, Esber N, Bouchard P. Fibroid growth and medical options for treatment. Fertil Steril 2014;102:630–9
   PubMed Web of Science ®Google Scholar
• Bouchard P, Chabbert-Buffet N, Fauser BC. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril 2011;96:1175–89
   PubMed Web of Science ®Google Scholar
• Donnez J, Hudecek R, Donnez O, et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril 2015;103:519–27.e513
   PubMed Web of Science ®Google Scholar
• Moravek MB, Yin P, Ono M, et al. Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications. Hum Reprod Update 2015;21:1–12
   PubMed Web of Science ®Google Scholar
• Whitaker LH, Murray AA, Matthews R, et al. Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium. Hum Reprod 2017;32:531–43
   PubMed Web of Science ®Google Scholar
• Williams AR, Bergeron C, Barlow DH, Ferenczy A. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathol 2012;31:556–69
   PubMed Web of Science ®Google Scholar
• Spitz IM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol 2009;21:318–24
   PubMed Web of Science ®Google Scholar
• Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012;366:409–20
   PubMed Web of Science ®Google Scholar
• Donnez J, Donnez O, Matule D, et al. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril 2016;105:165–73.e164
   PubMed Web of Science ®Google Scholar
• Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. BJOG 1990;97:734–9
   Web of Science ®Google Scholar
• Donnez O, Donnez J, Dolmans MM, et al. Low Pain score after total laparoscopic hysterectomy and same-day discharge within less than 5 hours: results of a prospective observational study. J Minim Invasive Gynecol 2015;22:1293–9
   PubMed Web of Science ®Google Scholar
• Courtoy GE, Donnez J, Marbaix E, Dolmans MM. In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment. Fertil Steril 2015;104:426–34.e421
   PubMed Web of Science ®Google Scholar
• Courtoy GE, Henriet P, Marbaix E, et al. Matrix metalloproteinase activity correlates with uterine myoma volume reduction after ulipristal acetate treatment. J Clin Endocrinol Metab 2018;103:1566–73
   PubMed Web of Science ®Google Scholar
• Courtoy GE, Donnez J, Ambroise J, et al. Gene expression changes in uterine myomas in response to ulipristal acetate treatment. Reprod Biomed Online 2018;37:224–33
   PubMed Web of Science ®Google Scholar
• Fauser BC, Donnez J, Bouchard P, et al. Safety after extended repeated use of ulipristal acetate for uterine fibroids. PloS One 2017;12:e0173523
   PubMed Web of Science ®Google Scholar
• Donnez J. Liver injury and ulipristal acetate: an overstated tragedy? Fertil Steril 2018;110:593–5
   PubMed Web of Science ®Google Scholar